Medtronic Gains Market Share in Cardiac Ablation -- Company Talk
Dow Jones
Jun 04
Medtronic's Cardiac Ablation Solutions segment drove much of the company's fiscal fourth-quarter cardiovascular performance, with U.S. revenue more than doubling. The company says it gained an additional eight points of U.S. market share during the quarter. The growth reflects the continued rollout of the Affera mapping and ablation system, which CEO Geoff Martha cited as one of the company's highest-growth opportunities. The cardiovascular portfolio overall grew 10.1% organically in the quarter, with the Cardiac Rhythm & Heart Failure division up high-teens.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
(END) Dow Jones Newswires
June 03, 2026 12:20 ET (16:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.